The U.S. market's high prices create the large profit pool necessary to fund risky drug development. If the U.S. adopted price negotiation like other countries, the global incentive for pharmaceutical innovation would shrink, resulting in fewer new drugs being developed worldwide.

The administration is leveraging the U.S.'s market power to demand "most favored nation" pricing from pharmaceutical companies. This forces them to offer drugs at the lowest price available in any other developed nation, slashing costs for American consumers.

Jason Kelly argues against the "free market" view of pharma, noting U.S. consumers generate 70% of global drug profits. This market power means the U.S. is effectively paying for the R&D that builds up China's strategic biotech industry, a national security concern.

While MFN pricing is seen as a major threat, it could have an unexpected positive effect. It would force companies launching new drugs to establish a GDP-adjusted global price from the start, ending the current system where the U.S. effectively subsidizes lower prices elsewhere.

America's high drug prices, while socially debated, ensure that global biotech innovators, including those in China, prioritize bringing their best drugs to the US market. This guarantees American access to cutting-edge treatments developed anywhere.

The U.S. healthcare system, while messy, accounts for over half of the world's pharmaceutical R&D. Its semi-market-based incentives drive global innovation, a benefit that could be lost if the U.S. transitions to a single-payer model like those in other countries that rely on its discoveries.

To fix the R&D funding imbalance, the CEO proposes a 'one fair price' system. A drug would have one US price with no rebates, and a price in other developed nations would be indexed to their GDP per capita.

The gap between U.S. and international drug prices is a structural feature of the pharma economy. High profits from the U.S. market fund expensive R&D that ultimately benefits the rest of the world, which pays far less for the same innovations. This reframes the debate around high American healthcare costs.

Despite innovation emerging worldwide, the ultimate goal for any new drug inventor is U.S. approval. The primary driver is the potential for high drug prices in the American market, which ensures the U.S. remains the central hub for late-stage clinical development and benefits from global R&D.